SHS_211093 AUSK CROC 16157

A Phase III, Randomized, Double-Blind, Placebo controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn's Disease

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis factor inhibitors.
Phase III
All Other
Karlee Ausk, M.D.
Roche Holding AG (Hoffman-LaRoche)
Allison Everett
  • Swedish Medical Center